The Opportunity

The market for psychedelic-inspired medicines is one of the fastest-growing sectors in healthcare. Multiple publicly traded companies in this space are already valued at over one billion dollars — before receiving FDA approval. The sector as a whole exceeds ten billion dollars in total value. In August 2025, Gilgamesh Pharmaceuticals was acquired for 1.2 billion dollars.

EPIK offers investors a way to participate in this sector with significantly lower regulatory risk than existing public companies — because our medicines are already FDA-recognized.

Why Invest Now

• Animal testing is already underway — we are at a major value inflection point
• Labcorp delivered validation formulations in April 2026
• Our regulatory path is expected to be faster and less expensive than competitors
• We have reserved the Nasdaq ticker symbol EPIK — we are building toward a public listing
• Investors receive 30% discount to the valuation set at EPIK’s next priced equity financing round.

Investment Terms

• Structure: SAFE (Simple Agreement for Future Equity)
• Discount: 30% to the first priced round valuation
• Round size: $30 million
• Minimum investment: $55,000
• Who can invest: Accredited investors only
• Nasdaq ticker: EPIK (reserved)

What Happens
When You Inquire

When you submit an inquiry, a member of the EPIK team will respond shortly. You will be asked to sign a non-disclosure agreement, after which you will receive our confidential investor packet and comprehensive detailed scientific documentation.